子宫内膜癌
彭布罗利珠单抗
医学
食品药品监督管理局
疾病
入射(几何)
临床试验
肿瘤科
放射治疗
癌症
免疫疗法
内科学
微卫星不稳定性
重症监护医学
妇科
生物
药理学
等位基因
物理
光学
基因
微卫星
生物化学
作者
Rebecca Brooks,Gini F. Fleming,Ricardo R. Lastra,Nita K. Lee,John W. Moroney,Christina H. Son,K. Tatebe,J.L.T. Veneris
摘要
Abstract Endometrial cancer is the most common gynecologic cancer in the United States, and its incidence is rising. Although there have been significant recent advances in our understanding of endometrial cancer biology, many aspects of treatment remain mired in controversy, including the role of surgical lymph node assessment and the selection of patients for adjuvant radiation or chemotherapy. For the subset of women with microsatellite‐instable, metastatic disease, anti– programmed cell death protein 1 immunotherapy (pembrolizumab) is now approved by the US Food and Drug Administration, and numerous trials are attempting to build on this early success.
科研通智能强力驱动
Strongly Powered by AbleSci AI